Targeting dclk1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting il-6/stat3 signaling

HIGHLIGHTS

• who: Heshu Liu from the treatment [3, ]Initial classification of TNBC based on bulk mRNA profiles identified , molecular subtypes by Brian D. Lehmann et_al in , [5]. With the development of sequencing technology, a more comprehensive analysis based on transcriptomic and genomic data of TNBC patients was performed and four molecular subtypes were classified by Fudan University Shanghai Cancer Center (FUSCC) [6]. No matter how to categorize TNBC, the subtype enriched with stem cells was non-negligible and difficult to treat. CSCs are small population of cells displaying a u00adC, +/CD24- phenotype and high ALDH activity (ALDH+) in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.